Publication

Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study

Minović, I., Kieneker, L. M., Gansevoort, R. T., Eggersdorfer, M., Touw, D. J., Voerman, A-J., Connelly, M. A., Boer, R. A. D., Hak, E., Bos, J., Dullaart, R. P. F., Kema, I. P. & Bakker, S. J. L., 4-Sep-2020, In : Nutrients. 12, 9, p. 1-17 17 p., 2711.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Minović, I., Kieneker, L. M., Gansevoort, R. T., Eggersdorfer, M., Touw, D. J., Voerman, A-J., Connelly, M. A., Boer, R. A. D., Hak, E., Bos, J., Dullaart, R. P. F., Kema, I. P., & Bakker, S. J. L. (2020). Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study. Nutrients, 12(9), 1-17. [2711]. https://doi.org/10.3390/nu12092711

Author

Minović, Isidor ; Kieneker, Lyanne M ; Gansevoort, Ron T ; Eggersdorfer, Manfred ; Touw, Daan J ; Voerman, Albert-Jan ; Connelly, Margery A ; Boer, Rudolf A de ; Hak, Eelko ; Bos, Jens ; Dullaart, Robin P F ; Kema, Ido P ; Bakker, Stephan J L. / Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort : The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study. In: Nutrients. 2020 ; Vol. 12, No. 9. pp. 1-17.

Harvard

Minović, I, Kieneker, LM, Gansevoort, RT, Eggersdorfer, M, Touw, DJ, Voerman, A-J, Connelly, MA, Boer, RAD, Hak, E, Bos, J, Dullaart, RPF, Kema, IP & Bakker, SJL 2020, 'Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study', Nutrients, vol. 12, no. 9, 2711, pp. 1-17. https://doi.org/10.3390/nu12092711

Standard

Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort : The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study. / Minović, Isidor; Kieneker, Lyanne M; Gansevoort, Ron T; Eggersdorfer, Manfred; Touw, Daan J; Voerman, Albert-Jan; Connelly, Margery A; Boer, Rudolf A de; Hak, Eelko; Bos, Jens; Dullaart, Robin P F; Kema, Ido P; Bakker, Stephan J L.

In: Nutrients, Vol. 12, No. 9, 2711, 04.09.2020, p. 1-17.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Minović I, Kieneker LM, Gansevoort RT, Eggersdorfer M, Touw DJ, Voerman A-J et al. Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study. Nutrients. 2020 Sep 4;12(9):1-17. 2711. https://doi.org/10.3390/nu12092711


BibTeX

@article{ca2a9df03c984bdeba62429d97b96f89,
title = "Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study",
abstract = "BACKGROUND: a large number of studies have linked vitamin B6 to inflammation and cardiovascular disease in the general population. However, it remains uncertain whether vitamin B6 is associated with cardiovascular outcome independent of inflammation.METHODS: we measured plasma pyridoxal 5'-phosphate (PLP), as an indicator of vitamin B6 status, at baseline in a population-based prospective cohort of 6249 participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study who were free of cardiovascular disease. As indicators of low-grade systemic inflammation, we measured high-sensitivity C-reactive protein and GlycA; Results: median plasma PLP was 37.2 (interquartile range, 25.1-57.0) nmol/L. During median follow-up for 8.3 (interquartile range, 7.8-8.9) years, 409 non-fatal and fatal cardiovascular events (composite outcome) occurred. In the overall cohort, log transformed plasma PLP was associated with the composite outcome, independent of adjustment for age, sex, smoking, alcohol consumption, body mass index (BMI), estimated glomerular filtration rate (eGFR), total cholesterol:high-density lipoprotein (HDL)-cholesterol ratio, and blood pressure (adjusted hazard ratio per increment of log plasma PLP, 0.66; 95% confidence interval (CI), 0.47-0.93). However, adjustment for high-sensitivity C-reactive protein and GlycA increased the hazard ratio by 9% and 12% respectively, to non-significant hazard ratios of 0.72 (95% confidence interval, 0.51-1.01) and 0.74 (95% confidence interval, 0.53-1.05). The association of plasma PLP with cardiovascular risk was modified by gender (adjusted Pinteraction = 0.04). When stratified according to gender, in women the prospective association with cardiovascular outcome was independent of age, smoking, alcohol consumption, high-sensitivity C-reactive protein, and GlycA (adjusted hazard ratio, 0.50, 95% confidence interval, 0.27-0.94), while it was not in men (adjusted hazard, 0.99, 95% confidence interval, 0.65-1.51).CONCLUSIONS: in this population-based cohort, plasma PLP was associated with cardiovascular outcome, but this association was confounded by traditional risk factors and parameters of inflammation. Notably, the association of low plasma PLP with high risk of adverse cardiovascular outcome was modified by gender, with a stronger and independent association in women.",
author = "Isidor Minovi{\'c} and Kieneker, {Lyanne M} and Gansevoort, {Ron T} and Manfred Eggersdorfer and Touw, {Daan J} and Albert-Jan Voerman and Connelly, {Margery A} and Boer, {Rudolf A de} and Eelko Hak and Jens Bos and Dullaart, {Robin P F} and Kema, {Ido P} and Bakker, {Stephan J L}",
year = "2020",
month = sep,
day = "4",
doi = "10.3390/nu12092711",
language = "English",
volume = "12",
pages = "1--17",
journal = "Nutrients",
issn = "2072-6643",
publisher = "MDPI AG",
number = "9",

}

RIS

TY - JOUR

T1 - Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort

T2 - The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study

AU - Minović, Isidor

AU - Kieneker, Lyanne M

AU - Gansevoort, Ron T

AU - Eggersdorfer, Manfred

AU - Touw, Daan J

AU - Voerman, Albert-Jan

AU - Connelly, Margery A

AU - Boer, Rudolf A de

AU - Hak, Eelko

AU - Bos, Jens

AU - Dullaart, Robin P F

AU - Kema, Ido P

AU - Bakker, Stephan J L

PY - 2020/9/4

Y1 - 2020/9/4

N2 - BACKGROUND: a large number of studies have linked vitamin B6 to inflammation and cardiovascular disease in the general population. However, it remains uncertain whether vitamin B6 is associated with cardiovascular outcome independent of inflammation.METHODS: we measured plasma pyridoxal 5'-phosphate (PLP), as an indicator of vitamin B6 status, at baseline in a population-based prospective cohort of 6249 participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study who were free of cardiovascular disease. As indicators of low-grade systemic inflammation, we measured high-sensitivity C-reactive protein and GlycA; Results: median plasma PLP was 37.2 (interquartile range, 25.1-57.0) nmol/L. During median follow-up for 8.3 (interquartile range, 7.8-8.9) years, 409 non-fatal and fatal cardiovascular events (composite outcome) occurred. In the overall cohort, log transformed plasma PLP was associated with the composite outcome, independent of adjustment for age, sex, smoking, alcohol consumption, body mass index (BMI), estimated glomerular filtration rate (eGFR), total cholesterol:high-density lipoprotein (HDL)-cholesterol ratio, and blood pressure (adjusted hazard ratio per increment of log plasma PLP, 0.66; 95% confidence interval (CI), 0.47-0.93). However, adjustment for high-sensitivity C-reactive protein and GlycA increased the hazard ratio by 9% and 12% respectively, to non-significant hazard ratios of 0.72 (95% confidence interval, 0.51-1.01) and 0.74 (95% confidence interval, 0.53-1.05). The association of plasma PLP with cardiovascular risk was modified by gender (adjusted Pinteraction = 0.04). When stratified according to gender, in women the prospective association with cardiovascular outcome was independent of age, smoking, alcohol consumption, high-sensitivity C-reactive protein, and GlycA (adjusted hazard ratio, 0.50, 95% confidence interval, 0.27-0.94), while it was not in men (adjusted hazard, 0.99, 95% confidence interval, 0.65-1.51).CONCLUSIONS: in this population-based cohort, plasma PLP was associated with cardiovascular outcome, but this association was confounded by traditional risk factors and parameters of inflammation. Notably, the association of low plasma PLP with high risk of adverse cardiovascular outcome was modified by gender, with a stronger and independent association in women.

AB - BACKGROUND: a large number of studies have linked vitamin B6 to inflammation and cardiovascular disease in the general population. However, it remains uncertain whether vitamin B6 is associated with cardiovascular outcome independent of inflammation.METHODS: we measured plasma pyridoxal 5'-phosphate (PLP), as an indicator of vitamin B6 status, at baseline in a population-based prospective cohort of 6249 participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study who were free of cardiovascular disease. As indicators of low-grade systemic inflammation, we measured high-sensitivity C-reactive protein and GlycA; Results: median plasma PLP was 37.2 (interquartile range, 25.1-57.0) nmol/L. During median follow-up for 8.3 (interquartile range, 7.8-8.9) years, 409 non-fatal and fatal cardiovascular events (composite outcome) occurred. In the overall cohort, log transformed plasma PLP was associated with the composite outcome, independent of adjustment for age, sex, smoking, alcohol consumption, body mass index (BMI), estimated glomerular filtration rate (eGFR), total cholesterol:high-density lipoprotein (HDL)-cholesterol ratio, and blood pressure (adjusted hazard ratio per increment of log plasma PLP, 0.66; 95% confidence interval (CI), 0.47-0.93). However, adjustment for high-sensitivity C-reactive protein and GlycA increased the hazard ratio by 9% and 12% respectively, to non-significant hazard ratios of 0.72 (95% confidence interval, 0.51-1.01) and 0.74 (95% confidence interval, 0.53-1.05). The association of plasma PLP with cardiovascular risk was modified by gender (adjusted Pinteraction = 0.04). When stratified according to gender, in women the prospective association with cardiovascular outcome was independent of age, smoking, alcohol consumption, high-sensitivity C-reactive protein, and GlycA (adjusted hazard ratio, 0.50, 95% confidence interval, 0.27-0.94), while it was not in men (adjusted hazard, 0.99, 95% confidence interval, 0.65-1.51).CONCLUSIONS: in this population-based cohort, plasma PLP was associated with cardiovascular outcome, but this association was confounded by traditional risk factors and parameters of inflammation. Notably, the association of low plasma PLP with high risk of adverse cardiovascular outcome was modified by gender, with a stronger and independent association in women.

U2 - 10.3390/nu12092711

DO - 10.3390/nu12092711

M3 - Article

C2 - 32899820

VL - 12

SP - 1

EP - 17

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 9

M1 - 2711

ER -

ID: 134182337